Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes Than with Either Monotherapy in Patients with Early Rheumatoid Arthritis: 8-Year Results of An Open-Label Extension of a Phase 3 Trial

被引：0

作者：

Breedveld, Ferdinand C. ^{[1
]}

Keystone, Edward ^{[2
]}

van der Heijde, Desiree ^{[1
]}

Landewe, Robert ^{[3
]}

Smolen, Josef ^{[4
,5
]}

Guerette, Benoit ^{[6
]}

McIlraith, Melissa ^{[6
]}

Kupper, Hartmut ^{[7
]}

Liu, Shufang ^{[8
]}

Wolfe, Benjamin ^{[8
]}

Kavanaugh, Arthur ^{[9
]}

机构：

[1] Leiden Univ, Med Ctr, Leiden, Netherlands

[2] Univ Toronto, Toronto, ON, Canada

[3] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands

[4] Med Univ Vienna, Vienna, Austria

[5] Hietzing Hosp, Vienna, Austria

[6] Abbott, Rungis, France

[7] Abbott GmbH & Co KG, Ludwigshafen, Germany

[8] Abbott, Abbott Pk, IL USA

[9] Univ Calif San Diego, San Diego, CA 92103 USA

来源：

ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1231

引用

页码：S481 / S481

页数：1

共 50 条

[31] Long-Term Safety and Efficacy of Voxelotor for Patients with Sickle Cell Disease: Results from an Open-Label Extension of the Phase 3 HOPE Trial
Achebe, Maureen
Hassab, Hoda
Alkindi, Salam
Brown, R. Clark Clark
Telfer, Paul
Biemond, Bart J.
Gordeuk, Victor R.
Lipato, Thokozeni
Tonda, Margaret
Gray, Sarah
Howard, Joanna
BLOOD, 2021, 138
[32] Correlations Between Early MRI Parameters and Long-Term Clinical Outcomes in Phase 3 and Open-Label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study
Arnold, Douglas
Freeman, Leorah
Hartung, Hans-Peter
Montalban, Xavier
Cohen, Jeffrey
Bar-Or, Amit
Steinman, Lawrence
DeLuca, John
Sheffield, James
Cheng, Chun-Yen
Riolo, Jon
Pachai, Chahin
Cree, Bruce A. C.
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1050 - 1051
[33] Efficacy and safety of nateglinide plus sitagliptin combination therapy in type 2 diabetes patients inadequately controlled by sitagliptin monotherapy: a phase 3, multicenter, open-label, long-term study
Hirose T.
Saitoh C.
Oikawa I.
Kondo N.
Diabetology International, 2018, 9 (3) : 168 - 178
[34] Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients
Smolen, Josef S.
van Vollenhoven, Ronald
Kavanaugh, Arthur
Strand, Vibeke
Vencovsky, Jiri
Schiff, Michael
Landewe, Robert
Haraoui, Boulos
Arendt, Catherine
Mountian, Irina
Carter, David
van der Heijde, Desire
ARTHRITIS RESEARCH & THERAPY, 2015, 17
[35] Long-Term Benefits of 4-Weekly Certolizumab Pegol Combination and Monotherapy On Household Productivity and Social Participation in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study
Strand, Vibeke
Purcaru, Oana
van Vollenhoven, Ronald F.
Choy, Ernest
Fleischmann, Roy
ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S567 - S567
[36] LONG-TERM BENEFITS OF 4-WEEKLY CERTOLIZUMAB PEGOL COMBINATION AND MONOTHERAPY ON HOUSEHOLD PRODUCTIVITY AND SOCIAL PARTICIPATION IN RHEUMATOID ARTHRITIS: 5 YEAR RESULTS FROM AN OPEN LABEL EXTENSION STUDY
Strand, V
Purcaru, O.
Van Vollenhoven, R.
Choy, E.
Fleischmann, R.
VALUE IN HEALTH, 2012, 15 (07) : A451 - A452
[37] Longterm Effect of Delaying Combination Therapy with Tumor Necrosis Factor Inhibitor in Patients with Aggressive Early Rheumatoid Arthritis: 10-year Efficacy and Safety of Adalimumab from the Randomized Controlled PREMIER Trial with Open-label Extension
Keystone, Edward C.
Breedveld, Ferdinand C.
van der Heijde, Desiree
Landewe, Robert
Florentinus, Stefan
Arulmani, Udayasankar
Liu, Shufang
Kupper, Hartmut
Kavanaugh, Arthur
JOURNAL OF RHEUMATOLOGY, 2014, 41 (01) : 5 - 14
[38] Long-Term Safety of Lacosamide as Adjunctive Therapy in Patients with Uncontrolled Partial-Onset Seizures: Results from a Phase III Open-Label Extension Trial
Husain, Aatif
Faught, Raymond Edward
Chung, Steve
Isojarvi, Jouko
McShea, Cindy
Doty, Pamela
NEUROLOGY, 2011, 76 (09) : A291 - A291
[39] Long-Term (104-Week) Safety and Efficacy of Monotherapy with Apremilast in DMARD-Naive Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial and Open-Label Extension (PALACE 4)
Wells, Alvin
Edwards, Christopher
Adebajo, Adewale O.
Kivitz, Alan J.
Bird, Paul
Shah, Kamal
Hu, ChiaChi
Stevens, Randall M.
Aelion, Jacob A.
ARTHRITIS & RHEUMATOLOGY, 2014, 66 (12) : 3539 - 3539
[40] LONG-TERM (104-WEEK) EFFICACY AND SAFETY OF APREMILAST MONOTHERAPY IN DMARD-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS: A PHASE 3, RANDOMIZED, CONTROLLED TRIAL AND OPEN-LABEL EXTENSION (PALACE 4)
Wells, A.
Edwards, C.
Adebajo, A.
Kivitz, A.
Bird, P.
Shah, K.
Hu, C.
Aelion, J.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 863 - 864

← 1 2 3 4 5 →